2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide
目录号 : GC305612-(E-2-decenoylamino)ethyl2-(cyclohexylethyl)sulfide是一种由压力诱发的溃疡和低毒性抑制剂,可以在压力引起的溃疡大鼠中,维持磷脂酶A2(phospholipaseA2)和前列腺素E2(prostaglandinE2)的含量水平。
Cas No.:137089-36-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide is a compound that inhibits stress-induced ulcer and low toxicity, and can maintain the content of phospholipase A2 and prostaglandin E2 in ulcerated rats induced by water immersed restrained stress.
2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide (compd.III-1α, 100 mg/kg, p.o.) maintains the relative content of Fr.I hexose, lipid peroxide and phospholipase A2 (PLA2) in normal level in ulcerated rats induced by water immersed restrained stress via dosing twice a day for 3 day (b.i.d. for 3 d). 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide (100 mg/kg, p.o.) reduces the hexosamine content equally with the control group 4 h after the stress loading, and then markedly increases 7 h after stress loading. 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide (25 mg/kg, p.o.) blocks the reduction of prostaglandin E2 (PGE2) and PGI2 in early phase and accelerates the increase of PGE2 and PGI2 in the late phase of the stress. 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide (25 mg/kg, p.o.) also significantly accelerates the cell proliferation in fundic glands in gastric mucosa of mice[1].
[1]. Kohda I, et al. Further studies on the anti-ulcerogenic effects of compound, 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide. Chem Pharm Bull (Tokyo). 1991 Jul;39(7):1832-6.
Cas No. | 137089-36-2 | SDF | |
Canonical SMILES | CCCCCCC/C=C/C(NCCSCCC1CCCCC1)=O | ||
分子式 | C20H37NOS | 分子量 | 339.58 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.9448 mL | 14.7241 mL | 29.4481 mL |
5 mM | 0.589 mL | 2.9448 mL | 5.8896 mL |
10 mM | 0.2945 mL | 1.4724 mL | 2.9448 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。